Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2002 1
2003 4
2004 4
2005 5
2006 1
2007 3
2008 2
2009 1
2010 1
2013 1
2014 1
2015 2
2016 13
2017 12
2018 14
2019 16
2020 22
2021 23
2022 22
2023 15
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Results by year

Filters applied: . Clear all
Page 1
LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease.
Jennings D, Huntwork-Rodriguez S, Vissers MFJM, Daryani VM, Diaz D, Goo MS, Chen JJ, Maciuca R, Fraser K, Mabrouk OS, van de Wetering de Rooij J, Heuberger JAAC, Groeneveld GJ, Borin MT, Cruz-Herranz A, Graham D, Scearce-Levie K, De Vicente J, Henry AG, Chin P, Ho C, Troyer MD. Jennings D, et al. Among authors: groeneveld gj. Mov Disord. 2023 Mar;38(3):386-398. doi: 10.1002/mds.29297. Epub 2023 Feb 18. Mov Disord. 2023. PMID: 36807624 Clinical Trial.
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients.
Vissers MFJM, Heuberger JAAC, Groeneveld GJ, Oude Nijhuis J, De Deyn PP, Hadi S, Harris J, Tsai RM, Cruz-Herranz A, Huang F, Tong V, Erickson R, Zhu Y, Scearce-Levie K, Hsiao-Nakamoto J, Tang X, Chang M, Fox BM, Estrada AA, Pomponio RJ, Alonso-Alonso M, Zilberstein M, Atassi N, Troyer MD, Ho C. Vissers MFJM, et al. Among authors: groeneveld gj. Clin Transl Sci. 2022 Aug;15(8):2010-2023. doi: 10.1111/cts.13317. Epub 2022 Jun 1. Clin Transl Sci. 2022. PMID: 35649245 Free PMC article. Clinical Trial.
A Biomarker Study in Patients with GBA1-Parkinson's Disease and Healthy Controls.
den Heijer JM, Cullen VC, Pereira DR, Yavuz Y, de Kam ML, Grievink HW, Moerland M, Leymarie N, Khatri K, Sollomoni I, Spitalny L, Dungeon L, Hilt DC, Justman C, Lansbury P, Groeneveld GJ. den Heijer JM, et al. Among authors: groeneveld gj. Mov Disord. 2023 May;38(5):783-795. doi: 10.1002/mds.29360. Epub 2023 Mar 14. Mov Disord. 2023. PMID: 36916660
Modeling buprenorphine reduction of fentanyl-induced respiratory depression.
Olofsen E, Algera MH, Moss L, Dobbins RL, Groeneveld GJ, van Velzen M, Niesters M, Dahan A, Laffont CM. Olofsen E, et al. Among authors: groeneveld gj. JCI Insight. 2022 May 9;7(9):e156973. doi: 10.1172/jci.insight.156973. JCI Insight. 2022. PMID: 35316224 Free PMC article. Clinical Trial.
The use of biomarkers in human pharmacology (Phase I) studies.
Cohen AF, Burggraaf J, van Gerven JM, Moerland M, Groeneveld GJ. Cohen AF, et al. Among authors: groeneveld gj. Annu Rev Pharmacol Toxicol. 2015;55:55-74. doi: 10.1146/annurev-pharmtox-011613-135918. Epub 2014 Oct 6. Annu Rev Pharmacol Toxicol. 2015. PMID: 25292425 Review.
139 results